CR20210462A - Anticuerpos anti-trem1 y métodos relacionados - Google Patents
Anticuerpos anti-trem1 y métodos relacionadosInfo
- Publication number
- CR20210462A CR20210462A CR20210462A CR20210462A CR20210462A CR 20210462 A CR20210462 A CR 20210462A CR 20210462 A CR20210462 A CR 20210462A CR 20210462 A CR20210462 A CR 20210462A CR 20210462 A CR20210462 A CR 20210462A
- Authority
- CR
- Costa Rica
- Prior art keywords
- trem1
- related methods
- trem1 antibodies
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802161P | 2019-02-06 | 2019-02-06 | |
| US201962889994P | 2019-08-21 | 2019-08-21 | |
| PCT/US2020/016949 WO2020163564A2 (en) | 2019-02-06 | 2020-02-06 | Anti-trem1 antibodies and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210462A true CR20210462A (es) | 2021-12-13 |
Family
ID=71947128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210462A CR20210462A (es) | 2019-02-06 | 2020-02-06 | Anticuerpos anti-trem1 y métodos relacionados |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125732A1 (es) * | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | Anticuerpos anti-trem1 |
| CN114807031A (zh) * | 2022-05-13 | 2022-07-29 | 山东赛恩福干细胞工程集团有限公司 | 一种人外周血免疫细胞库和干细胞库的构建方法 |
| KR20260017009A (ko) | 2023-04-21 | 2026-02-04 | 셀시우스 테라퓨틱스, 인코포레이티드 | 항-trem1 항체 제제, 조성물 및 이의 용도 |
| WO2025201129A1 (zh) * | 2024-03-28 | 2025-10-02 | 北京丹序生物制药有限公司 | 一种抗触发受体-1抗体或其抗原结合片段及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787995B1 (en) | 1992-01-28 | 2004-09-07 | Fujitsu Limited | Full color surface discharge type plasma display device |
| US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| CA2331386A1 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| JP2002164544A (ja) | 2000-11-28 | 2002-06-07 | Sony Corp | 半導体装置 |
| WO2002058721A1 (en) | 2000-12-08 | 2002-08-01 | Baylor College Of Medicine | Trem-1 splice variant for use in modifying immune responses |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0122546D0 (en) | 2001-09-19 | 2001-11-07 | Univ Cranfield | Optical fibre long period grating with thin film overlays |
| GB0401730D0 (en) | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8289572B2 (en) | 2005-09-22 | 2012-10-16 | Ricoh Production Print Solutions LLC | Estimation of ink/toner coverage when printing |
| JP2007298739A (ja) | 2006-04-28 | 2007-11-15 | Toshiba Corp | 組立て方法及び画像形成装置 |
| RU2490223C2 (ru) | 2006-11-21 | 2013-08-20 | ГАРСИА Карлос Хавиер ФЕРНАНДЕЗ | Способ предварительного смешивания и сухого заполнения волокном |
| JP5334995B2 (ja) | 2008-01-16 | 2013-11-06 | エヌエックスピー ビー ヴィ | 相変化材料層を有する多層構造およびその製造方法 |
| EP2268755A2 (en) | 2008-03-14 | 2011-01-05 | 3M Innovative Properties Company | Stretch releasable adhesive article |
| US8419721B2 (en) | 2009-07-29 | 2013-04-16 | Alcon Lensx, Inc. | Optical system for ophthalmic surgical laser |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP5470093B2 (ja) | 2010-02-26 | 2014-04-16 | 株式会社ニフコ | 保持装置 |
| US20120317870A1 (en) | 2011-06-20 | 2012-12-20 | Gregory Allen Pratt | Method and apparatus for use in the extermination of bed bug infestations |
| US9068575B2 (en) | 2011-06-28 | 2015-06-30 | Caterpillar Inc. | Hydraulic control system having swing motor energy recovery |
| RS57827B1 (sr) | 2012-02-15 | 2018-12-31 | Novo Nordisk As | Antitela koja vezuju protein 1 prepoznavanja peptidoglikana |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| JP6411218B2 (ja) | 2012-02-15 | 2018-10-24 | ノヴォ ノルディスク アー/エス | 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体 |
| US20150376294A1 (en) * | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| BR112015020862B1 (pt) | 2013-02-28 | 2021-05-25 | Hewlett-Packard Development Company, L.P. | barra de impressão moldada |
| WO2014207910A1 (ja) | 2013-06-28 | 2014-12-31 | 株式会社 東芝 | テレビジョン装置、及びリモートコントローラ |
| FR3016679B1 (fr) | 2014-01-22 | 2016-01-22 | Air Liquide | Robinet pour bouteille de fluide sous pression et bouteille correspondante |
| US9448150B2 (en) | 2014-02-03 | 2016-09-20 | Cameron International Corporation | Method and apparatus for determining kinematic viscosity through the transmission and reception of ultrasonic energy |
| CN106536559B (zh) | 2014-07-17 | 2021-04-27 | 诺和诺德股份有限公司 | 定点诱变trem-1抗体以降低黏度 |
| EP3026061A1 (en) | 2014-11-26 | 2016-06-01 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
| US10615407B2 (en) | 2014-08-14 | 2020-04-07 | Battelle Memorial Institute | Na—FeCl2 ZEBRA type battery |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| IL254039B2 (en) * | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| EP3173438A1 (en) | 2015-11-30 | 2017-05-31 | SABIC Global Technologies B.V. | Use of polypropylene composition for coffee cartridge |
| WO2017127933A1 (en) | 2016-01-29 | 2017-08-03 | The Governing Council Of The University Of Toronto | Frizzled protein-binding agents and methods of use thereof |
| JP7023853B2 (ja) * | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗trem1抗体及びその使用方法 |
| DE102016205647B4 (de) | 2016-04-06 | 2018-11-29 | Voith Patent Gmbh | Ringgatter für eine hydraulische Maschine und Verfahren zum Schließen |
| PE20190115A1 (es) * | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| EP3263167B1 (en) | 2016-06-30 | 2023-06-28 | Wellspect AB | Urinary catheter with varying properties |
| PL3609540T3 (pl) | 2017-04-14 | 2023-03-27 | Bolt Biotherapeutics, Inc. | Sposób syntezy immunokoniugatu |
| EP3664845A4 (en) | 2017-08-08 | 2021-03-10 | Pionyr Immunotherapeutics, Inc. | COMPOSITIONS AND METHODS OF DEACTIVATION OF MYELOID CELLS EXPRESSING TREM1 |
-
2020
- 2020-02-06 MX MX2021009500A patent/MX2021009500A/es unknown
- 2020-02-06 EP EP20752176.6A patent/EP3921344A4/en active Pending
- 2020-02-06 PE PE2021001282A patent/PE20212269A1/es unknown
- 2020-02-06 CN CN202080027026.9A patent/CN113748132B/zh active Active
- 2020-02-06 SG SG11202108570SA patent/SG11202108570SA/en unknown
- 2020-02-06 BR BR112021015479A patent/BR112021015479A2/pt unknown
- 2020-02-06 TW TW109103757A patent/TWI870382B/zh active
- 2020-02-06 CR CR20210462A patent/CR20210462A/es unknown
- 2020-02-06 WO PCT/US2020/016949 patent/WO2020163564A2/en not_active Ceased
- 2020-02-06 AU AU2020218525A patent/AU2020218525A1/en active Pending
- 2020-02-06 KR KR1020217028210A patent/KR20210126638A/ko active Pending
- 2020-02-06 CA CA3128053A patent/CA3128053A1/en active Pending
- 2020-02-06 JP JP2021545857A patent/JP7492522B2/ja active Active
- 2020-02-06 PH PH1/2021/551903A patent/PH12021551903A1/en unknown
- 2020-04-17 US US16/852,294 patent/US10836828B2/en active Active
- 2020-10-08 US US17/066,401 patent/US12065491B2/en active Active
-
2021
- 2021-07-13 IL IL284818A patent/IL284818A/en unknown
- 2021-08-05 CL CL2021002075A patent/CL2021002075A1/es unknown
- 2021-08-06 DO DO2021000165A patent/DOP2021000165A/es unknown
- 2021-08-18 CO CONC2021/0010887A patent/CO2021010887A2/es unknown
-
2022
- 2022-09-16 ZA ZA2022/10284A patent/ZA202210284B/en unknown
-
2024
- 2024-05-17 JP JP2024080881A patent/JP7759996B2/ja active Active
- 2024-07-09 US US18/767,771 patent/US20250179185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI870382B (zh) | 2025-01-21 |
| CA3128053A1 (en) | 2020-08-13 |
| CN113748132A (zh) | 2021-12-03 |
| JP2022523145A (ja) | 2022-04-21 |
| CO2021010887A2 (es) | 2021-09-09 |
| CN113748132B (zh) | 2026-01-27 |
| JP7759996B2 (ja) | 2025-10-24 |
| US10836828B2 (en) | 2020-11-17 |
| JP2024105632A (ja) | 2024-08-06 |
| CL2021002075A1 (es) | 2022-04-01 |
| EP3921344A2 (en) | 2021-12-15 |
| EP3921344A4 (en) | 2022-10-12 |
| IL284818A (en) | 2021-08-31 |
| US12065491B2 (en) | 2024-08-20 |
| WO2020163564A2 (en) | 2020-08-13 |
| US20250179185A1 (en) | 2025-06-05 |
| PE20212269A1 (es) | 2021-11-30 |
| US20210101983A1 (en) | 2021-04-08 |
| DOP2021000165A (es) | 2021-09-30 |
| MX2021009500A (es) | 2021-09-08 |
| KR20210126638A (ko) | 2021-10-20 |
| BR112021015479A2 (pt) | 2021-12-28 |
| WO2020163564A3 (en) | 2020-09-24 |
| SG11202108570SA (en) | 2021-09-29 |
| ZA202210284B (en) | 2023-03-29 |
| TW202037613A (zh) | 2020-10-16 |
| PH12021551903A1 (en) | 2022-08-01 |
| US20200255529A1 (en) | 2020-08-13 |
| JP7492522B2 (ja) | 2024-05-29 |
| AU2020218525A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
| CL2021002075A1 (es) | Anticuerpos anti-trem1 y métodos relacionados. | |
| ZA202104246B (en) | Humanized anti-human-pd-1 antibody | |
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| MX374810B (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX388410B (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| CR20230169A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
| PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| JOP20220161A1 (ar) | جسم مضاد لـ lilrb1 واستخداماته | |
| AR093357A1 (es) | Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
| MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. | |
| EA202091458A1 (ru) | Анти-trem2 антитела и связанные с ними способы | |
| AR118028A1 (es) | Anticuerpos anti-trem1 y métodos relacionados | |
| EA202192182A1 (ru) | Антитела к trem1 и соответствующие способы | |
| AR133072A2 (es) | Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr | |
| EA202090201A2 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| AR115992A2 (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| PL409845A1 (pl) | Przeciwciała poliklonalne klasy IgY specyficzne wobec peptydowego składnika ściany komórkowej bakterii oraz ich zastosowanie |